| 11/09/2026 3:30 PM | NLS Pharmaceutics (1783036) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/09/2026 8:06 AM | NLS Pharmaceutics (1783036) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/04/2026 7:16 AM | NLS Pharmaceutics (1783036) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/22/2026 11:15 PM | NLS Pharmaceutics (1783036) Filer | Form EFFECT | |
| 09/18/2026 3:20 PM | NLS Pharmaceutics (1783036) Filer | Form POS AM | |
| 08/26/2026 11:15 PM | NLS Pharmaceutics (1783036) Filer | Form EFFECT | |
| 08/24/2026 3:05 PM | NLS Pharmaceutics (1783036) Filer | Form D Notice of Exempt Offering of Securities | |
| 08/20/2026 3:15 PM | NLS Pharmaceutics (1783036) Filer | Form F-3 Registration statement for securities of certain foreign private issuers | |
| 07/31/2026 8:11 AM | NLS Pharmaceutics (1783036) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/15/2026 8:41 AM | NLS Pharmaceutics (1783036) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/08/2026 8:15 AM | NLS Pharmaceutics (1783036) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
Get the Latest News and Ratings for NCEL and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for NLS Pharmaceutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 07/01/2026 8:30 AM | NLS Pharmaceutics (1783036) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/30/2026 3:30 PM | NLS Pharmaceutics (1783036) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/17/2026 11:15 PM | NLS Pharmaceutics (1783036) Filer | Form EFFECT | |
| 06/15/2026 7:42 AM | NLS Pharmaceutics (1783036) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/10/2026 3:16 PM | NLS Pharmaceutics (1783036) Filer | Form F-3/A | |
| 06/05/2026 3:32 PM | NLS Pharmaceutics (1783036) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/27/2026 7:00 AM | NLS Pharmaceutics (1783036) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/17/2026 11:15 PM | NLS Pharmaceutics (1783036) Filer | Form EFFECT | |
| 05/12/2026 8:51 PM | NLS Pharmaceutics (1783036) Filer | Form D Notice of Exempt Offering of Securities | |
| 05/11/2026 4:06 PM | NLS Pharmaceutics (1783036) Filer | Form F-3 Registration statement for securities of certain foreign private issuers | |
| 05/06/2026 11:15 PM | NLS Pharmaceutics (1783036) Filer | Form EFFECT | |
| 04/30/2026 7:18 AM | NLS Pharmaceutics (1783036) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/29/2026 3:15 PM | NLS Pharmaceutics (1783036) Filer | Form 20-F Registration statement / Annual report / Transition report | |
| 04/29/2026 3:05 PM | NLS Pharmaceutics (1783036) Issuer Revel Michel (2095518) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/29/2026 3:05 PM | NLS Pharmaceutics (1783036) Issuer Samuel Olivier (2120179) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/20/2026 6:40 AM | NLS Pharmaceutics (1783036) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/01/2026 4:03 PM | NLS Pharmaceutics (1783036) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/18/2026 6:00 AM | NLS Pharmaceutics (1783036) Issuer Oren Liora (2120185) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 03/18/2026 6:09 AM | Galili Tamar (2120183) Reporting NLS Pharmaceutics (1783036) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/18/2026 5:55 AM | Iohan Eran Israel (2116977) Reporting NLS Pharmaceutics (1783036) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/18/2026 5:57 AM | Molakandov Kfir (2120197) Reporting NLS Pharmaceutics (1783036) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/18/2026 6:01 AM | NLS Pharmaceutics (1783036) Issuer Samuel Olivier (2120179) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 03/18/2026 6:04 AM | Hagai Omri (2117767) Reporting NLS Pharmaceutics (1783036) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/18/2026 6:05 AM | NLS Pharmaceutics (1783036) Issuer Revel Michel (2095518) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 03/18/2026 6:07 AM | NLS Pharmaceutics (1783036) Issuer Twito Ronen (2095438) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 03/18/2026 5:43 AM | NLS Pharmaceutics (1783036) Issuer Zwyer Alexander (1861769) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 03/09/2026 6:21 AM | NLS Pharmaceutics (1783036) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/12/2026 6:13 AM | NLS Pharmaceutics (1783036) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 01/29/2026 6:13 AM | NLS Pharmaceutics (1783036) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 01/12/2026 6:12 AM | NLS Pharmaceutics (1783036) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
The Democrats can’t stop this (Ad) Porter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypassing Congress under a national emergency.
His new briefing outlines three steps to prepare and names a core group of assets tied to the initiative that he says could surge.
He points to the 1970s Nixon-era reset, which reportedly minted an average of 1,300 new millionaires a day for over half a century. Get Porter Stansberry's briefing on Trump's new dollar and the three steps he outlines. |
| 01/05/2026 6:20 AM | NLS Pharmaceutics (1783036) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/11/2025 8:22 AM | NLS Pharmaceutics (1783036) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/20/2025 3:16 PM | NLS Pharmaceutics (1783036) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/18/2025 11:15 PM | NLS Pharmaceutics (1783036) Filer | Form EFFECT | |
| 11/18/2025 11:15 PM | NLS Pharmaceutics (1783036) Filer | Form EFFECT | |
| 11/17/2025 6:06 AM | NLS Pharmaceutics (1783036) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |